$GILD Company News Lobbyists for insurers, big pharma

New Post Public Reply Private Reply Replies (0) Message Board

Jun 3, 2014 at 10:37 AM

$GILD Company News

Lobbyists for insurers, big pharma trade barbs over high drug costs 3:10 p.m. June 2, 2014 - blogs.marketwatch.com
Industry titan UnitedHealth misses boom in sector 10:53 a.m. May 29, 2014 - Russ Britt
Gilead says its drug gives hepatitis C patients more cost-effective cure 5:06 p.m. April 30, 2014 - blogs.marketwatch.com
Why a diverse ETF portfolio is right for these times 6:29 a.m. April 30, 2014 - John Prestbo
Internet, biotech could spawn next Apple: Allianz CIO 7:12 a.m. April 29, 2014 - Barbara Kollmeyer
What Obamacare problems? Aetna results not showing any ill effects 12:34 p.m. April 24, 2014 - blogs.marketwatch.com
U.S. stocks tumble; S&P 500 ends 6-day run 4:46 p.m. April 23, 2014 - Anora Mahmudova
Apple, Facebook stuck in red ahead of earnings 3:02 p.m. April 23, 2014 - Saumya Vaishampayan
U.S. stock futures pause after six-session win streak 8:57 a.m. April 23, 2014 - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. April 23, 2014 - blogs.marketwatch.com
Apple, Facebook, Boeing are stocks to watch 5:30 a.m. April 23, 2014 - Sue Chang
Gilead shares climb; AT&T, Amgen shares fall 5:55 p.m. April 22, 2014 - Myra P. Saefong
Gilead scores big on earnings with new drug, but investors getting wary 5:46 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead earnings buoyed by Hepatitis-C drug 5:04 p.m. April 22, 2014 - Anna Prior
Gilead Sciences shares up 4.5% in after-hours trade 4:35 p.m. April 22, 2014 - Myra P. Saefong
Gilead beats expectations; Sovaldi sales hit $2.3 bln 4:22 p.m. April 22, 2014 - Claudia Assis
Gilead: Hep C drug Sovaldi sells $2.27 billion 4:17 p.m. April 22, 2014 - Claudia Assis
Gilead Sciences Q1 non GAAP EPS $1.48 vs. 48c 4:15 p.m. April 22, 2014 - Claudia Assis
Should doctors care what treatments cost? 4:14 p.m. April 22, 2014 - blogs.marketwatch.com
S&P 500, Nasdaq extend win streak to 6 sessions: Stock market live blog recap 3:56 p.m. April 22, 2014 - blogs.marketwatch.com

Applied Genetic (AGTC) Soars: Stock Up 44.1% - Tale of the Tape 58 min ago - Zacks.com
Gilead CLL drug effective in Phase 2 trial 9:30 a.m. Today - Seeking Alpha
Puma Biotechnology (PBYI) Crumbles: Stock Plunges by 25.3% - Tale of the Tape 8:45 a.m. Today - Zacks.com
Ariad Pharmaceuticals (ARIA) Catches Eye: Stock Up 7.43% - Tale of the Tape 8:44 a.m. Today - Zacks.com
UPDATE: Gilead Reports Updated Phase 2 Results for Investigational GS-9973, Showed 49% Overall Response Rate with Est. Progression-Free Survival Rate at 24 Weeks 70% 7:33 a.m. Today - benzinga.com
Quebec Becomes First Province to Reimburse Sovaldi® for the Treatment of Chronic Hepatitis C 5:59 a.m. Today - CNW Group
Quebec Becomes First Province to Reimburse Sovaldi® for the Treatment of Chronic Hepatitis C 9:20 p.m. June 2, 2014 - CNW Group
Patent infringement suit dismissed 6:30 p.m. June 2, 2014 - Seeking Alpha
Roche Acquires Genia Technologies - Analyst Blog 4:40 p.m. June 2, 2014 - Zacks.com
Merck Presents Positive Trial Results For Cancer Drug 4:12 p.m. June 2, 2014 - Investors Business Daily
Myriad Genetics to Unveil BRACAnalysis, HRD Data - Analyst Blog 3:30 p.m. June 2, 2014 - Zacks.com
Why Vertex Pharmaceuticals Will Likely Climb to New High 1:26 p.m. June 2, 2014 - TheStreet.com
Value Of U.S. Equity Buybacks In May Drops 12:53 p.m. June 2, 2014 - benzinga.com
Encouraging Data on Pharmacyclics/J&J Drug - Analyst Blog 12:10 p.m. June 2, 2014 - Zacks.com
NPS Pharma on Shire's Radar? - Analyst Blog 11:30 a.m. June 2, 2014 - Zacks.com
Stock Market News for June 02, 2014 - Market News 10:06 a.m. June 2, 2014 - Zacks.com
Retrophin (RTRX) Jumps: Stock Adds 13.5% in Session - Tale of the Tape 9:25 a.m. June 2, 2014 - Zacks.com
Allergan Inc. (AGN) in Focus: Stock Rises 5.65% - Tale of the Tape 8:44 a.m. June 2, 2014 - Zacks.com
Analyst Cancer and Biotech Stock Picks From ASCO 7:57 a.m. June 2, 2014 - 247WallSt.com
Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients 7:35 a.m. May 31, 2014 - TheStreet.com

Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia 8:30 a.m. Today - BusinessWire - BZX
Stocks Coverage on Biotech Equities -- Research on Gilead Sciences, ARIAD Pharma, Rexahn Pharma, and Geron 7:10 a.m. May 30, 2014 - PR Newswire - PRF
Clinical Study Results, Schedule of Upcoming Conferences, Dividend Declaration, and Services Agreement - Analyst Notes on Gilead, Quest Diagnostics, Sarepta Therapeutics, Incyte and Centene 5:10 a.m. May 28, 2014 - PR Newswire - PRF
AHF: ‘Negligent Corporate Welfare’ Pushes Gilead to Top of S&P 500 5:40 p.m. May 22, 2014 - BusinessWire - BZX
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF
Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults 5:00 p.m. May 20, 2014 - BusinessWire - BZX
Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology 7:40 a.m. May 20, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the 2014 UBS Healthcare Conference on Tuesday, May 20 5:00 p.m. May 19, 2014 - BusinessWire - BZX
Critical Alerts For Goldman Sachs, Noodles & Company, Starbucks, Gilead Sciences, and Time Warner Cable Released By InvestorsObserver 9:31 a.m. May 14, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14 5:00 p.m. May 13, 2014 - BusinessWire - BZX
Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 4:31 p.m. May 9, 2014 - BusinessWire - BZX
Cancer Diagnostics Partnering Terms and Agreements 5:41 p.m. May 7, 2014 - PR Newswire - PRF
Gilead Announces $5 Billion Share Repurchase Program 5:17 p.m. May 7, 2014 - BusinessWire - BZX
Medivir: a Supplemental New Drug Application Has Been Submitted to the U.S. FDA for Simeprevir in Combination with Sofosbuvir 8:06 a.m. May 7, 2014 - BusinessWire - BZX
Biotech Stocks Review -- Research on Retrophin, Merrimack, Gilead Sciences, and Rexahn Pharma 12:37 p.m. May 6, 2014 - PR Newswire - PRF
BetterInvesting Magazine Releases July Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use 4:15 p.m. May 2, 2014 - PR Newswire - PRF
Parion Sciences Reacquires Rights to Epithelial Sodium Channel Inhibitors 9:00 a.m. April 30, 2014 - PR Newswire - PRF
The World Market for Orphan Drugs 6:59 p.m. April 29, 2014 - PR Newswire - PRF
Critical Alerts For Comcast, Gilead Sciences, Ciena, Adobe Systems, and Celldex Therapeutics Released By InvestorsObserver 9:31 a.m. April 29, 2014 - PR Newswire - PRF
Federal Circuit Rules for Axinn Client Natco Pharma Ltd. in Tamiflu Patent Appeal 1:50 p.m. April 25, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PathoSearch: A New Era in Pathology With Visual Search

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Ajman Spotlights Tourism at Arabian Travel Market 2026

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

D-Wave Faces Legal Questions After CFO Exit and Losses

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

ARTiSTORY's Strategic Advance in Cultural IP Licensing

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

PureHealth's Acid Reflux Solutions: An Investor's Insight

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Silk Road Maritime Extends Its Global Reach in 2026

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Countries Eye New Investment Paths at CIFIT 2026

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

IASLC Boosts Global Thoracic Cancer Collaboration

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...